论文部分内容阅读
PI3K/AKT/mTOR通路的异常活化在结直肠癌的发生发展中起到重要作用,以此通路为靶点的药物已成为结直肠癌治疗的研究热点,临床前和临床试验研究证明,针对PI3K/AKT/mTOR通路的多种抑制剂具有抗肿瘤活性。越来越多的临床数据显示,PTEN缺乏或PIK3CA基因突变对PI3K/AKT/mTOR通路抑制剂敏感,KRAS突变则预示着耐药;寻找针对这一通路抑制剂敏感的优势人群也成为结直肠癌的研究热点;此外,PI3K/AKT/mTOR通路也会影响常规治疗的疗效,因此PI3K/AKT/mTOR通路抑制剂联合细胞毒治疗方案在结直肠癌中可能起到协同作用。
The abnormal activation of PI3K / AKT / mTOR pathway plays an important role in the development of colorectal cancer. Drug targeting this pathway has become a hot research topic in the treatment of colorectal cancer. Preclinical and clinical studies have shown that PI3K / Various inhibitors of the AKT / mTOR pathway have anti-tumor activity. More and more clinical data show that PTEN deficiency or PIK3CA gene mutation is sensitive to inhibitor of PI3K / AKT / mTOR pathway and KRAS mutation indicates the resistance; finding the predominant population sensitive to this pathway inhibitor also becomes colorectal cancer In addition, PI3K / AKT / mTOR pathway will also affect the efficacy of conventional treatment, PI3K / AKT / mTOR pathway inhibitor and cytotoxic therapy may play a synergistic effect in colorectal cancer.